Skip to main content

Table 3 FOIAS of phases 1–3 and PVM (PrimaVistaMode) in FOI at baseline and after 12 months (n = 35 for FOIAS parameters

From: Fluorescence optical imaging for treatment monitoring in patients with early and active rheumatoid arthritis in a 1-year follow-up period

  Month of visit 0 (V0)* Month of visit 12 (V12)* Difference between V12 and V0* p value (Wilcoxon signed rank test)
Phase 1 5 (1.04;26)
(0;70.91)
1 (0;4)
(0;32)
−3 (− 17;0)
(−69.91;12)
0.00445 (sig.)
Phase 2 16 (10.5;25)
(1;40)
16 (9.5;24)
(2;43)
2 (−4.5;6.81)
(− 18;18)
0.6004
Phase 3 1 (0;2.5)
(0;15)
1 (0;4)
(0;10)
0 (− 1;1.5)
(− 12;9)
0.5451
PVM 9 (4.5;13)
(0;24)
9 (3.5;14)
(0;26)
−1 (−4;4)
(− 15;14)
0.7461
  1. Phases 1–3 and PVM (PrimaVistaMode) of FOI at baseline and after 12 months (n = 35): FOIAS fluorescence optical imaging activity score; *median (1. quartile; 3. quartile); (min; max); significance level = 0.05